Search
aclidinium bromide (Tudorza Pressair, Bretaris, Eklira)
Indications:
- long-term maintenance treatment of bronchospasm associated with COPD
Contraindication:
- not a rescue inhaler
Dosage:
- a dry powder inhaler used twice daily
Adverse effects:
- paradoxical bronchospasm
- new or worsened acute narrow-angle glaucoma
- new or worsened urinary retention
- does not worsen cardiovascular outcomes in COPD [3]
Mechanism of action:
- antimuscarinic agent
- by inhibiting the muscarinic M3 receptor, it relaxes smooth muscle resulting in bronchodilation
- affinity for muscarinic receptors (M1-M5) [2]
Interactions
drug adverse effects of parasympatholytics
General
parasympatholytic (anticholinergic, antimuscarinic agent)
Database Correlations
PUBCHEM correlations
References
- FDA News Release: July 23, 2012
FDA approves Tudorza Pressair to treat chronic obstructive
pulmonary disease
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm313052.htm
- Prescriber's Letter 19(12): 2012
Tudorza Pressair (Aclidinium)
Detail-Document#: 281209
(subscription needed) http://www.prescribersletter.com
- Wise RA et al.
Effect of aclidinium bromide on major cardiovascular events and
exacerbations in high-risk patients with chronic obstructive
pulmonary disease: The ASCENT-COPD randomized clinical trial.
JAMA 2019 May 7; 321:1693
PMID: 31063575
https://jamanetwork.com/journals/jama/fullarticle/2732574